IL325099A - Oral solid estrogen receptor antagonist dosage forms - Google Patents

Oral solid estrogen receptor antagonist dosage forms

Info

Publication number
IL325099A
IL325099A IL325099A IL32509925A IL325099A IL 325099 A IL325099 A IL 325099A IL 325099 A IL325099 A IL 325099A IL 32509925 A IL32509925 A IL 32509925A IL 325099 A IL325099 A IL 325099A
Authority
IL
Israel
Prior art keywords
dosage forms
oral dosage
estrogen receptor
solid oral
receptor degraders
Prior art date
Application number
IL325099A
Other languages
English (en)
Hebrew (he)
Inventor
Iii Royal J Haskell
Joseph P Reo
Original Assignee
Arvinas Operations Inc
Iii Royal J Haskell
Joseph P Reo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc, Iii Royal J Haskell, Joseph P Reo filed Critical Arvinas Operations Inc
Publication of IL325099A publication Critical patent/IL325099A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL325099A 2023-06-12 2025-12-03 Oral solid estrogen receptor antagonist dosage forms IL325099A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363472523P 2023-06-12 2023-06-12
PCT/US2024/033417 WO2024258856A1 (fr) 2023-06-12 2024-06-11 Formes posologiques orales solides d'agents de dégradation des récepteurs des œstrogènes

Publications (1)

Publication Number Publication Date
IL325099A true IL325099A (en) 2026-02-01

Family

ID=91738206

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325099A IL325099A (en) 2023-06-12 2025-12-03 Oral solid estrogen receptor antagonist dosage forms

Country Status (7)

Country Link
KR (1) KR20260022394A (fr)
CN (1) CN121311218A (fr)
AU (1) AU2024303588A1 (fr)
IL (1) IL325099A (fr)
MX (1) MX2025014795A (fr)
TW (1) TW202500155A (fr)
WO (1) WO2024258856A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
MX2011009053A (es) 2009-03-09 2012-04-02 Spi Pharma Inc Excipientes de compresion directa con alta capacidad de compactacion y durables y sistemas de excipiente.
AU2016272881C1 (en) * 2015-06-04 2019-10-03 Pfizer Inc. Solid dosage forms of palbociclib
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
CA3152401A1 (fr) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Procedes de traitement du cancer du sein avec des derives de tetrahydronaphtalene en tant qu'agents de degradation du recepteur des estrogenes
CN116390916A (zh) * 2020-09-14 2023-07-04 阿尔维纳斯运营股份有限公司 用于靶向降解雌激素受体的化合物的结晶形式
CN119604285A (zh) * 2022-03-25 2025-03-11 深圳市药欣生物科技有限公司 Protac化合物的药物组合物及其用途

Also Published As

Publication number Publication date
KR20260022394A (ko) 2026-02-19
WO2024258856A1 (fr) 2024-12-19
AU2024303588A1 (en) 2025-12-18
MX2025014795A (es) 2026-01-07
CN121311218A (zh) 2026-01-09
TW202500155A (zh) 2025-01-01

Similar Documents

Publication Publication Date Title
IL319242A (en) Estrogen Receptor Blocker Dosage Regimen
GB2595776B (en) Therapeutic solid dosage forms
ZA202102263B (en) Oral formulations of kappa opioid receptor agonists
EA201201403A1 (ru) Очень низкодозированные твердые пероральные лекарственные формы для гзт
IL318878A (en) Oral solid dosage forms containing cannabinoids
IL325099A (en) Oral solid estrogen receptor antagonist dosage forms
IL320847A (en) Oral liquid formulations of hydrocortisone
CA3295229A1 (fr) Formes posologiques orales solides d'agents de dégradation des récepteurs des œstrogènes
ZA200705012B (en) Oral solid dosage forms containing a low dose of estradiol
IL313886A (en) Processes for the preparation of selective compounds of estrogen receptors
HK40127185A (zh) 雌激素受体降解剂的给药方案
CA224159S (en) Oral dosage tablet
IL319657A (en) Glucocorticoid receptor modulator formulations
IL317910A (en) Oral dosage forms of ELRAGLUSIB
CA3274497A1 (fr) Formes galéniques d'un antagoniste du récepteur des œstrogènes
GB202100470D0 (en) Solid tablet dosage for of ridinilazole
IL314134A (en) Oral dosage forms
HUE066812T2 (hu) Az utidelone szilárd, orális készítménye
IL310321A (en) Lipid-based formulation for oral administration of BRADYKININ B2 receptor antagonists
AU2024325502A1 (en) Oral pharmaceutical dosage form providing immediate release of vidofludimus
CA3300667A1 (fr) Forme posologique pharmaceutique orale fournissant une libération immédiate de vidofludimus
GB202007254D0 (en) Delivery device for units of an oral dosage form
GB202004831D0 (en) Delivery device for oral dosage forms
IL325323A (en) Solid oral podafenone formulation
CA223192S (en) Mouthpiece for oral development